Associate Director, Biostatistics Clinical Late Stage Revolution Medicines IncAssociate Director, Biostatistics Clinical Late StageRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Associate Director, Clinical Biomarker Development Revolution Medicines IncAssociate Director, Clinical Biomarker DevelopmentRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline.
Associate Director, Regulatory Systems Revolution Medicines IncAssociate Director, Regulatory SystemsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. This individual will serve as the business owner for key regulatory systems and partner closely with Regulatory Affairs, Regulatory Operations, IT, Quality, Clinical, and external vendors to deliver scalable, compliant, and efficient business solutions.
Regional Insights and Engagement Director, Lung, Southeast Revolution Medicines IncRegional Insights and Engagement Director, Lung, SoutheastRedwood City, CARemote$231,000–$254,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of RevMed's US commercialization strategy; Uncovers, prioritizes, and communicates market insights, challenges/barriers, and solutions to the organization.
Executive Marketing Director - Neurodegenerative (NDG) Genentech IncExecutive Marketing Director - Neurodegenerative (NDG)South San Francisco, CA$265,700–$493,400 / yearThis Executive Marketing Director (EMD) is responsible for leading the development of the inaugural Therapeutic Area and Marketing Vision for Genentech Neurodegeneration (NDG) including promising, Phase 3 assets in Alzheimer's Disease and Parkinson's Disease and driving significant changes in US Commercial/Medical/Government organization to prepare for for our first launch in the large, evolving, and competitive NDG markets. Leads and contributes to the broader 1Marketing community at Genentech, participates in initiatives that have broad functional impact or impact across multiple therapeutic areas, offers functional expertise and supports capability development for the entire Marketing function, and advances progress towards our CMG outcomes.
Director Program Management Abbott LaboratoriesDirector Program ManagementSanta Clara, CA$149,300–$298,700 / yearThe Director Program Management provides overall leadership, direction and co-ordination to the Abbott New Zealand integration project team, maintaining awareness for the need for on-going change and continuous improvement, monitoring performance versus project milestones and timelines and taking corrective action as necessary to meet targets for project completion schedule, budgets and start up. Provides on-going updates to key leaders in Division, Corporate and other support groups including the Project Steering Committee, Program Management team, Commercial, and functional leadership.
Director, Stability Management, Analytical Development and Quality Control Revolution Medicines IncDirector, Stability Management, Analytical Development and Quality ControlRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Collaborate cross-functionally with teams in drug substance, drug product, supply chain, quality, regulatory, sourcing and other related team to ensure alignment of stability design and achieve stability study objectives.
Associate Director, Clinical Data Management Revolution Medicines IncAssociate Director, Clinical Data ManagementRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Program Management Revolution Medicines IncAssociate Director, Program ManagementRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Identify critical path activities, resource constraints, risks, and conflicts that could impact the timelines or budget; work with subject matter experts to construct appropriate mitigation plans.
Director Neuroscience Commercial Strategy - Corporate Business Strategy Office AbbVie IncDirector Neuroscience Commercial Strategy - Corporate Business Strategy OfficeSouth San Francisco, CAThis position will foster positive working relationships and be highly collaborative with each franchise brand teams, Finance, Medical, R&D, Market Access, Health Economics and Outcomes Research (HEOR), Market Analytics and Business Insights (MABI), Sales Training, Sales Force Effectiveness, Regulatory, Customer Experience, and other cross franchise teams to gain input into developing strategic and operational projects. The Director of Neuroscience Commercial Strategy - Corporate Business Strategy Office (CBSO) will help drive commercial & market innovation strategy and business operations projects across the Neuroscience business, that includes Psychiatry, Migraine, Parkinson's Disease, and BOTOX Therapeutics.
Director, Program Management Revolution Medicines IncDirector, Program ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Director, Program Management partners with the Project Team Leader (PTL) on the translation of program strategy into an efficient execution plan; they understand the competitive landscape and clinical context to manage the cross-functional dependencies and connections.
Associate Director, Revenue Accounting and Finance Revolution Medicines IncAssociate Director, Revenue Accounting and FinanceRedwood City, CA$186,000–$233,000 / yearPrepare and analyze monthly product revenue and gross-to-net close activities, including the calculation, recording, and monitoring of gross-to-net accruals and related reserve balances for prompt pay discounts, copay and patient assistance programs, returns, Medicaid, Medicare Part D, 340B, VA/DoD, and other forms of variable consideration. Manage the day-to-day partnership with the external government pricing consultant, including coordinating required data submissions, reviewing government pricing calculations and related outputs, and supporting accuracy and compliance across government channels, including Medicaid, Medicare Part D, 340B, and VA/FSS programs.
Associate Director AI Transformation AbbVie IncAssociate Director AI TransformationSouth San Francisco, CAResponsibilities: Lead workstreams as part of strategic transformation initiatives (both AI-driven and non-AI focused) across the enterprise, managing and driving alignment among stakeholders across the enterprise including senior leadership, cross-functional teams, and external partners. Applicable only to applicants applying to a position in any location with pay disclosure requirements under state or local law: The compensation range described below is the range of possible base pay compensation that the Company believes in good faith it will pay for this role at the time of this posting based on the job grade for this position.
Associate Director, Commercial Regulatory Affairs Revolution Medicines IncAssociate Director, Commercial Regulatory AffairsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As part of the Regulatory Affairs function, the Associate Director will work under supervision to provide strategic regulatory advice on advertising/promotion and medical materials to the US organization for assigned products in accordance with business goals and objectives, FDA regulations/guidances, pharma guidelines, and company policy.
NewDirector Facilities Management Stamford American International HospitalDirector Facilities ManagementPalo Alto, CA$83.98–$111.27 / hourSets vision for and leads the management of the Facilities Management department at the Palo Alto hospital campus or the Property Facilities Management department at regional campuses and oversees all operational aspects of property / facilities management in a manner which protects, maintains and improves the value of the facilities. Coordinates and communicates work specifications, installation and space management; architectural and engineering, planning and design; new construction and/or renovation; maintenance and operations management; telecommunications integration, security and general administrative services.
Associate Director, Quality Validation Revolution Medicines IncAssociate Director, Quality ValidationRedwood City, CA$186,000–$233,000 / yearAs a key member of the Quality organization, the Associate Director, Quality Validation partners closely with cross-functional teams within Pharmaceutical Development & Manufacturing (PDM) and external partners to develop and maintain robust validation strategies, support commercial manufacturing and product disposition activities, drive continuous improvement, and ensure consistent execution of validation programs across the global external manufacturing network. The Opportunity: The Associate Director, Quality Validation is responsible for providing strategic quality leadership and oversight of validation programs supporting Drug Substance (DS), Drug Product Intermediate (DPI), Drug Product (DP), packaging, and distribution activities across the company's global network of CDMOs, packaging partners, and suppliers.
Director, US Strategic Pricing, Pipeline Revolution Medicines IncDirector, US Strategic Pricing, PipelineRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Effectively partner with internal stakeholders to develop relationships to drive price strategy access including Global Market Access, Pricing, and Development, US Market Access Marketing, Field Key Account teams.
Senior Director, Head of Transactions & Partnering Revolution Medicines IncSenior Director, Head of Transactions & PartneringRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role partners closely with Business Development leadership and cross-functional stakeholders across Research, Development, Commercial, Finance, Legal, Intellectual Property, and Executive Management to advance high-priority opportunities from initial assessment through successful execution.
Executive Director, GCP QA Good Clinical Practice, Quality Assurance Revolution Medicines IncExecutive Director, GCP QA Good Clinical Practice, Quality AssuranceRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Regional Insights and Engagement Director, Lung, Central Rockies Revolution Medicines IncRegional Insights and Engagement Director, Lung, Central RockiesRedwood City, CARemote$231,000–$254,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of RevMed's US commercialization strategy; Uncovers, prioritizes, and communicates market insights, challenges/barriers, and solutions to the organization.
Associate Director, Clinical Science Arcus Biosciences IncAssociate Director, Clinical ScienceHayward, CARemote$200,000–$210,000 / yearProvide organizational support for Data Monitoring Committees and other applicable data review committees, including operationalizing the charter, preparing updates and data reviews, execution of meetings and adjudications, and communication of synthesized data reports. This role will work on cross-functional study management teams for the design, execution, and monitoring of clinical trials, as well as data interpretation and communication to both internal and external stakeholders.
Director, DMPK Assembly Biosciences IncDirector, DMPKSouth San Francisco, CA$228,000–$252,100 / yearSummary: We are seeking an experienced, creative, and highly motivated expert with industry research experience in DMPK focused on small molecule lead optimization for discovery research programs, preclinical and clinical drug development. In addition to overseeing a group of external professionals, this position will be responsible for leading DMPK interactions with medicinal chemists to facilitate the identification of molecules meeting criteria for clinical development and support preclinical and clinical development.
Software Development Director Agilent Technologies IncSoftware Development DirectorSanta Clara, CA$213,696–$333,900 / yearThis role manages a distributed organization, including direct reports, an international supervisor, and offshore vendor teams. Agilent Technologies, Inc., is committed to creating and maintaining an inclusive in the workplace where everyone is welcome, and strives to support candidates with disabilities.
Associate Director, Environmental Health and Safety Revolution Medicines IncAssociate Director, Environmental Health and SafetyRedwood City, CA$186,000–$233,000 / yearManage occupational health program activities in partnership with internal stakeholders and external providers, including workplace injury and illness investigation and tracking, animal allergen questionnaire administration and follow-up, hepatitis B vaccination program support, ergonomics program coordination and continuous improvement, and maintenance of related documentation, metrics, and compliance records. Support Facilities Safety Programs through cross-functional collaboration and subject matter expertise, ensuring effective implementation of programs such as electrical safety, lockout/tagout, fall protection, confined space, heat illness prevention, and hot work, while maintaining clear role distinction from program ownership.
Senior Director, Head of Search & Evaluation Revolution Medicines IncSenior Director, Head of Search & EvaluationRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Working in close partnership with leaders across Research, Development, Commercial, Corporate Strategy, Portfolio Management, and Executive Management, this individual will lead the company''s search and evaluation activities across discovery and clinical-stage opportunities.
Associate Director, Business Operations Revolution Medicines IncAssociate Director, Business OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role is ideal for a Associate Director -level professional who thrives on execution, can drive several projects in parallel, can navigate a matrix environment, and brings strong project leadership, communication and change management experience.
Director, IT Infrastructure & Operations Nurix Therapeutics IncDirector, IT Infrastructure & OperationsBrisbane, CAYou lead a team that spans enterprise architecture, system administration, and cybersecurity operations, with the service desk delivered through a mix of staff and managed service providers. A measurable track record managing a managed service provider portfolio, including real consolidation or vendor transitions with accountability for outcomes.
Director HEOR Strategy Dermatology AbbVie IncDirector HEOR Strategy DermatologySouth San Francisco, CAThe Director, Health Economics & Outcomes Research (HEOR) leads the development & execution of projects for on-market and/or pipeline development assets, who is the brand/asset leader representing HEOR on cross functional asset/brand teams and in the pipeline commercialization teams. Applicable only to applicants applying to a position in any location with pay disclosure requirements under state or local law: The compensation range described below is the range of possible base pay compensation that the Company believes in good faith it will pay for this role at the time of this posting based on the job grade for this position.
Senior Director, Global Value Access and Pricing, NSCLC Revolution Medicines IncSenior Director, Global Value Access and Pricing, NSCLCRedwood City, CARemote$232,000–$290,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As the Global Value & Access lead on Disease Area Strategy Teams and governance forums, the Senior Director influences clinical development, indication sequencing, lifecycle management, launch planning, and business development decisions to maximize long-term asset value and sustainable patient access.
Associate Director, Product Design-Mobile Abbott LaboratoriesAssociate Director, Product Design-MobileAlameda, CA$148,700–$297,300 / yearCollaborate Cross-Functionally: Partner closely with product management, engineering, brand, and marketing to deliver cohesive, high-impact experiences across mobile and web platforms. This role is ideal for a strategic design leader who thrives in fast-paced environments, is deeply passionate about user-centered design, and is excited to shape the future of health technology at scale.
NewLab Supervisor – Molecular Genetic Pathology and Clinical Genomics Stamford American International HospitalLab Supervisor – Molecular Genetic Pathology and Clinical GenomicsPalo Alto, CA$66.52–$88.14 / hourSupervises the work of laboratory personnel engaged in performing routine and specialized technical procedures, including planning day to day laboratory work activities, evaluating work performed and handling procedural technical and non-technical laboratory problems. Under the guidance of the section Medical director, develops and implements department specific processes/procedures and quality control programs to ensure reliability of testing procedures, proper function of laboratory equipment, and compliance to safety/health and state/federal/licensing regulations.
Senior Director, Global CMC Lead Revolution Medicines IncSenior Director, Global CMC LeadRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director, Global CMC Lead will provide cross-functional leadership and accountability for defining and executing integrated CMC strategies across development-stage and late-stage small molecule programs.
Director, IT Operations Revolution Medicines IncDirector, IT OperationsRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: 15+ years of progressive IT experience, including 5+ years in IT Operations, Infrastructure, or Service Delivery leadership roles within a medium-to-large enterprise environment.
Associate Director, Global Omnichannel Solutions Delivery Revolution Medicines IncAssociate Director, Global Omnichannel Solutions DeliveryRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The individual will play a critical role in supporting global expansion by establishing scalable solutions, enabling adoption of global platforms, and ensuring new capabilities, brands, and regions can be added efficiently without rework or fragmentation.
Director, Portfolio Omnichannel Lung HCP Revolution Medicines IncDirector, Portfolio Omnichannel Lung HCPRedwood City, CA$211,000–$264,000 / yearThe Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director RA Global Regulatory Strategy AbbVie IncDirector RA Global Regulatory StrategySouth San Francisco, CAThe Director Regulatory Affairs Global Regulatory Lead (GRL I) in Global Regulatory Strategy is responsible for developing and implementing global regulatory strategies to secure and maintain market approval for product(s) in assigned therapeutic area. Applicable only to applicants applying to a position in any location with pay disclosure requirements under state or local law: The compensation range described below is the range of possible base pay compensation that the Company believes in good faith it will pay for this role at the time of this postingbased on the job grade for this position.
Associate Director, Clinical Quality Assurance Revolution Medicines IncAssociate Director, Clinical Quality AssuranceRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Director of Alumni Relations and Giving San Francisco University High SchoolDirector of Alumni Relations and GivingSan Francisco, CA$130,000–$160,000 / yearThe director is responsible for developing the strategy, programs, events, activities, and communications that deepen the school's relationship with alumni, engage alumni in the life of the school, support alumni philanthropy, and build on alumni's connections with one another. Planning and implementing ongoing alumni events, activities, and programs geared to engage alumni (and other past members of the school community, including faculty, trustees, and parents) locally, regionally, and nationally.
Senior Director, Compliance Training Revolution Medicines IncSenior Director, Compliance TrainingRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner closely with Learning & Development, Corporate Communications, Legal, HR, regional compliance staff (U.S., Europe, and Asia), and business stakeholders to ensure effective deployment, localization, communication, and reinforcement of training programs.
Regional Insights and Engagement Director, Northeast Revolution Medicines IncRegional Insights and Engagement Director, NortheastRedwood City, CARemote$231,000–$254,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of RevMed's US commercialization strategy; Uncovers, prioritizes, and communicates market insights, challenges/barriers, and solutions to the organization.
Executive Director, Early Clinical Development Revolution Medicines IncExecutive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Revolution Medicines IncAssociate Director, Clinical OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Proven experience working with investigators, external experts and regulatory agencies and oversight of Contract Research Organizations and third-party vendors including realigning with CRO partners when deliverables are at risk, negotiating solutions and leading After Action Reviews to share lessons learned.
Director, Regulatory Affairs Companion Diagnostics CDx Revolution Medicines IncDirector, Regulatory Affairs Companion Diagnostics CDxRedwood City, CA$211,000–$264,000 / yearRequired Skills, Experience and Education: Advanced degree or bachelor's degree in life sciences, molecular biology, biomedical engineering, pharmacy, medicine, or related scientific discipline with a minimum of 12+ years of pharmaceutical, biotechnology, diagnostics, or combination product experience, including at least 8 years in Regulatory Affairs supporting companion diagnostics or in vitro diagnostics. This individual will serve as the regulatory lead for companion diagnostic development programs, partnering closely with Clinical Development, Translational Medicine, Biomarker Sciences, Regulatory Science, Commercial, and external diagnostic partners to ensure successful co-development and global registration of therapeutic products and associated companion diagnostics.
Senior Director, Clinical Biomarker Operations Revolution Medicines IncSenior Director, Clinical Biomarker OperationsRedwood City, CA$244,000–$305,000 / yearThe Opportunity: Revolution Medicines is seeking a strategic and experienced leader to serve as Senior Director, Clinical Biomarker Operations, responsible for leading the operational execution of biomarker and companion diagnostic (CDx) strategies across early- and late-stage clinical development programs. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director of Marketing and Communication Santa Clara UniversityAssociate Director of Marketing and CommunicationSanta Clara, CA$85,400–$93,943 / yearReporting to the Assistant Dean of Marketing and Communications, this position supports the School's efforts to raise visibility, strengthen its brand, engage internal and external audiences, recruit and retain students and faculty, build alumni and corporate partnerships, and advance fundraising initiatives., These activities are critical to the School's efforts to market its programs, recruit and retain undergraduate and graduate students and faculty, develop a strong alumni base, develop and maintain internal and external partnerships, and raise funds to support the School.
Director, US Compliance Revolution Medicines IncDirector, US ComplianceRedwood City, CA$267,000–$306,000 / yearProvide timely, practical, and risk-based compliance advice and counsel on healthcare compliance and policy requirements related to Revolution Medicines interactions with the healthcare community, including disease education programs, promotional and nonpromotional activities, consulting engagements, advisory boards, external funding, patient assistance programs, patient advocacy group interactions, payer interactions, and other similar activities. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
NewAssociate Director, Scientific Communications & Publications - Remote Agios PharmaceuticalsAssociate Director, Scientific Communications & Publications - RemoteSan Francisco, CARemote$153,000–$230,000 / yearOperating at the intersection of strategy and execution, this role partners closely with cross-functional colleagues and external experts to deliver high‑impact publications and scientific communications that advance both patient care and scientific dialogue. The current base salary range for this position is expected to be between $153,000 and $230,000 annualized; final salary will be determined based on various factors including, but not limited to, years of relevant experience, job knowledge, skills and proficiency, degree/education, and internal comparators.
Sr. Manager / Associate Director, Quality Audits Personalis IncSr. Manager / Associate Director, Quality AuditsFremont, CA$165,000–$210,000 / yearRoot Cause & Investigation Leadership: Provide expert guidance and lead cross-functional investigation teams in executing comprehensive root cause analyses for CAPAs, deviations, and non-conformances stemming from internal and external audits. The successful candidate will have strong leadership skills and possess extensive experience managing Quality Management Systems (QMS) within highly regulated environments, driving compliance, governance, and continuous improvement across the organization with a high degree of autonomy.
Senior Director, Global Patient Safety Surveillance Revolution Medicines IncSenior Director, Global Patient Safety SurveillanceRedwood City, CA$244,000–$305,000 / yearProvide relevant subject matter expertise for the design, development, maintenance, and support of one or more core GPS processes (i.e. comparative benefit-risk, signal detection & management, risk management, aggregate reporting, etc.) in compliance with applicable Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP), Good Documentation Practices (GDocP), etc., in alignment with the company's mission and objectives. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Statistical Programming Revolution Medicines IncAssociate Director, Statistical ProgrammingRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function.